β1 integrins modulate cell adhesion by regulating insulin-like growth factor-II levels in the microenvironment

Cancer Research

Volumn 66, Issue 1, 2006, Pages 331-342

  Goel, Hira Lal ^a   Moro, Loredana ^a,b,d   King, Michael ^a,b   Teider, Natalia ^a   Centrella, Michael ^b   McCarthy, Thomas L ^b   Holgado Madruga, Marina ^c   Wong, Albert J ^c   Marra, Ersilia ^d   Languino, Lucia R ^a,b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; BINDING PROTEIN; GROWTH FACTOR RECEPTOR; LAMININ 1; MEMBRANE PROTEIN; MESSENGER RNA; PROTEIN TYROSINE PHOSPHATASE; SOMATOMEDIN B; GAB1 PROTEIN, HUMAN; LAMININ; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN; SIGNAL PEPTIDE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SRC HOMOLOGY 2 (SH2) DOMAIN CONTAINING PHOSPHATASES; SRC HOMOLOGY-2 (SH2) DOMAIN-CONTAINING PHOSPHATASES;

ANIMAL CELL; ARTICLE; BASEMENT MEMBRANE; CANCER CELL; CELL ADHESION; CELL INTERACTION; CELL PROLIFERATION; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; HUMAN CELL; MICROENVIRONMENT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN MOTIF; RECEPTOR DOWN REGULATION; ANIMAL; BIOSYNTHESIS; CHO CELL; CYTOPLASM; GENETIC TRANSFECTION; GENETICS; HAMSTER; MALE; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; PROTEIN TERTIARY STRUCTURE; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIGENS, CD29; CELL ADHESION; CHO CELLS; CRICETINAE; CYTOPLASM; HUMANS; INSULIN-LIKE GROWTH FACTOR II; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LAMININ; MALE; MICE; PHOSPHOPROTEINS; PROSTATIC NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE-PHOSPHATASE; RNA, MESSENGER; TRANSFECTION; UP-REGULATION;

EID: 31544472050     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2588     Document Type: Article

References (59)

1. Nagle RB. Role of the extracellular matrix in prostate carcinogenesis. J Cell Biochem 2004;91:36-40.
2. Sinha AA, Gleason DF, Wilson MJ, et al. Immunohistochemical localization of laminin in the basement membranes of normal, hyperplastic, and neoplastic human prostate. Prostate 1989;15:299-313.
3. Vesalainen S, Lipponen P, Talja M, Alhava E, Syrjanen K. Tumor vascularity and basement membrane structure as prognostic factors in T1-2MO prostaticadenocarcinoma. Anticancer Res 1994;14: 709-14.
4. Fuchs ME, Brawer MK, Rennels MA, Nagle RB. The relationship of basement membrane to histologic grade of human prostatic carcinoma. Mod Pathol 1989;2:105-11.
5. 4 integrins in human prostate cancer progresion. Cancer Metastasis Rev 1995;14:219-28.
6. 4 integrin and laminin-5 in human prostate carcinoma. Prostate 2001;46: 240-8.
7. Brar PK, Dalkin BL, Weyer C, Sallam K, Virtanen I, Nagle RB. Laminin α-1, α-3, and α-5 chain expression in human prepubertal benign prostate glands and adult benign and malignant prostate glands. Prostate 2003;55:65-70.
8. 1 is involved in kidney tubulogenesis in vitro. J Cell Sci 1996;109:2801-10.
9. Engvall E, Wewer UM. Domains of laminin. J Cell Biochem 1996;61:493-501.
10. Smyth N, Vatansever HS, Murray P, et al. Absence of basement membranes after targeting the LAMC1 gene results in embryonic lethality due to failure of endoderm differentiation. J Cell Biol 1999;144:151-60.
11. Fornaro M, Manes T, Languino LR. Integrins and prostate cancer metastases. Cancer Metastasis Rev 2001; 20:321-31.
12. Ruoslahti E. Fibronectin and its integrin receptors in cancer. Adv Cancer Res 1999;76:1-20.
13. Garrison JB, Kyprianou N. Novel targeting of apoptosis pathways for prostate cancer therapy. Curr Cancer Drug Targets 2004;4:85-95.
14. Hemler ME, Weitzman JB, Pasqualini R, Kawaguchi S, Kassner PD, Berdichevsky FB. Structure, biochemical properties, and biological functions of integrin cytoplasmic domains. In: Takada Y, editor. Integrins: the biological problems. Boca Raton: CRC Press Inc.; 1995. p. 1-35.
15. Brakebusch C, Bouvard D, Stanchi F, Sakai T, Fassler R. Integrins in invasive growth. J Clin Invest 2002;109: 999-1006.
16. Kinashi T, Escobedo JA, Williams LT, Takatsu K, Springer TA. Receptor tyrosine kinase stimulates cell-matrix adhesion by phosphatidylinositol 3-kinase and phospholipase C-γ 1 pathways. Blood 1995;86: 2086-90.
17. 1- integrin function by epidermal growth factor and heregulin-β has distinct requirements for erbB2 but a similar dependence on phosphoinositide 3-OH kinase. Mol Biol Cell 1999;10:2861-78.
18. Bruyninckx WJ, Comerford KM, Lawrence DW, Colgan SP. Phosphoinositide 3-kinase modulation of β (3)-integrin represents an endogenous "braking" mechanism during neutrophil transmatrix migration. Blood 2001;97:3251-8.
19. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002;110:673-87.
20. 1 integrin gene expression in mice. Genes Dev 1995;9: 1896-908.
21. 1 integrins in tumors. Semin Cancer Biol 1993;4:277-83.
22. 1 integrins in epithelial cells. Oncogene 2001;20:759-68.
23. 1 integrin down-regulates ICAM-1 expression and ICAM-1-dependent adhesion of lung cancer cells through focal adhesion kinase. Cancer Res 2001;61: 2022-30.
24. 1 integrins regulates metalloproteinase gene expression in fibroblasts adhering to fibronectin. J Cell Biol 1995;129:867-79.
25. Lafrenie RM, Bernier SM, Yamada KM. Adhesion to fibronectin or collagen I gel induces rapid, extensive, biosynthetic alterations in epithelial cells. J Cell Physiol 1998;175:163-73.
26. 1 subunit overexpressed in the SMMC-7721 cells regulates the promoter activity of p21 (CIP1) and enhances its transcription. FEBS Lett 2004;558:107-13.
27. 1C integrin in prostatic adenocarcinoma. J Clin Invest 1999;103:321-9.
28. 3 integrin expression up-regulates cdc2, which modulates cell migration. J Cell Biol 2003;161:817-26.
29. 1 subunit with a variant cytoplasmic domain. J Biol Chem 1992;267:7116-20.
30. 1C integrin in breast carcinomas correlates with high proliferative fraction, high histological grade, and larger size. Am J Pathol 2000;156:169-74.
31. 1 integrins. J Cell Biol 2004;166:407-18.
32. 1 integrins. Exp Mol Pathol 2001;70:239-47.
33. Fornaro M, Plescia J, Chheang S, et al. Fibronectin protects prostate cancer cells from tumor necrosis factor α-induced apoptosis via the AKT/Survivin pathway. J Biol Chem 2003;278:50402-11.
34. Wennerberg K, Lohikangas L, Gullberg D, Pfaff M, Johansson S, Fassler R. β1 integrin-dependent and -independent polymerization of fibronectin. J Cell Biol 1996;132:227-38.
35. 1 integrin gene in embryonic stem cells affects morphology, adhesion, and migration but not integration into the inner cell mass of blastocysts. J Cell Biol 1995;128:979-88.
36. 1A integrin cytoplasmic variants in modulating focal adhesion kinase, protein kinase B/AKT, and Ras/Mitogen- activated protein kinase pathways. Mol Biol Cell 2000;11:2235-49.
37. Holgado-Madruga M, Wong AJ. Gab1 is an integrator of cell death versus cell survival signals in oxidative stress. Mol Cell Biol 2003;23:4471-84.
38. Zhang SQ, Tsiaras WG, Araki T, et al. Receptor-specific regulation of phosphatidylinositol 3′-kinase activation by the protein tyrosine phosphatase Shp2. Mol Cell Biol 2002;22:4062-72.
39. McCarthy TL, Centrella M, Canalis E. Cyclic AMP induces insulin-like growth factor I synthesis in osteoblast-enriched cultures. J Biol Chem 1990;265: 15353-6.
40. 1C integrin in epithelial cells correlates with a non-proliferative phenotype: forced expression of inhibits prostate epithelial cell proliferation. Am J Pathol 1998; 153:1079-87.
41. Holgado-Madruga M, Wong AJ. Role of the Grb2-associated binder 1/SHP-2 interaction in cell growth and transformation. Cancer Res 2004;64:2007-15.
42. Languino LR, Plescia J, Duperray A, et al. Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1 dependent pathway. Cell 1993;73: 1423-34.
43. 1C integrin, an inhibitor of cell proliferation, in prostate carcinoma. Am J Pathol 1996;149:765-73.
44. Baserga R. The IGF-1 receptor in cancer research. Exp Cell Res 1999;253:1-6.
45. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655-7.
46. Rodriguez-Viciana P, Warne PH, Vanhaesebroeck B, Waterfield MD, Downward J. Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. EMBO J 1996;15:2442-51.
47. Brisken C, Ayyannan A, Nguyen C, et al. IGF-2 is a mediator of prolactin-induced morphogenesis in the breast. Dev Cell 2002;3:877-87.
48. Kang-Park S, Lee YI. PTEN modulates insulin-like growth factor II (IGF-II)-mediated signaling; the protein phosphatase activity of PTEN downregulates IGF-II expression in hepatoma cells. FEBS Lett 2003; 545:203-8.
49. 1 integrin in breast carcinoma cells. Cancer Res 2004;64:4711-6.
50. 1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts. Cancer Res 2005;65: 6692-700.
51. Tennant MK, Thrasher JB, Twomey PA, Drivdahl RH, Birnbaum RS, Plymate SR. Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J Clin Endocrinol Metab 1996;81:3774-82.
52. Cardillo MR, Monti S, Di Silverio F, Gentile V, Sciarra F, Toscano V. Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer. Anticancer Res 2003;23:3825-35.
53. Kaplan PJ, Mohan S, Cohen P, Foster BA, Greenberg NM. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res 1999;59: 2203-9.
54. Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 2000;85:4258-65.
55. Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR, Rosenfeld RG. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab 1993;76:1031-5.
56. Winnay JN, Bruning JC, Burks DJ, Kahn CR. Gab-1-mediated IGF-1 signaling in IRS-1-deficient 3T3 fibroblasts. J Biol Chem 2000;275:10545-50.
57. Gu H, Neel BG. The "Gab" in signal transduction. Trends Cell Biol 2003;13:122-30.
58. O'Reilly AM, Neel BG. Structural determinants of SHP-2 function and specificity in Xenopus mesoderm induction. Mol Cell Biol 1998;18:161-77.
59. Wu CJ, O'Rourke DM, Feng GS, Johnson GR, Wang Q, Greene MI. The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors. Oncogene 2001;20: 6018-25.